Screener
Travere Therapeutics, Inc. TVTX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| Cash Flows From Financing Activities: | ||
| Payment of guaranteed minimum royalty | (525) | (525) |
| Proceeds from exercise of stock options | 4,729 | 4,243 |
| Net cash provided by financing activities | 4,204 | 3,718 |
| Effect of exchange rate changes on cash | (60) | 548 |
| Net (decrease) increase in cash and cash equivalents | (14,673) | 3,362 |
| Cash and cash equivalents, beginning of year | 93,035 | 58,535 |
| Cash and cash equivalents, end of period | $78,362 | $61,897 |
Item 1. Financial Statements
FAQ
- What is Travere Therapeutics, Inc.'s financing cash flow?
- Travere Therapeutics, Inc. (TVTX) reported financing cash flow of $4.2M in Q1 2026.
- How has Travere Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Travere Therapeutics, Inc.'s financing cash flow increased by 13.1% year-over-year, from $3.72M to $4.2M.
- What is the long-term trend for Travere Therapeutics, Inc.'s financing cash flow?
- Over 3 years (2021 to 2024), Travere Therapeutics, Inc.'s financing cash flow has grown at a -15.6% compound annual growth rate (CAGR), from $231.68M to $139.42M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Travere Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude